ErbB2/Her2: Small Molecules and Peptides
ErbB2, also called Neu and Her2, is a transmembrane glycoprotein in the ErbB family of tyrosine kinase receptors for EGF superfamily growth factors. ErbB2 is widely expressed in epithelial cells and over-expressed in a large number of breast carcinomas. ErbB2 has no identified ligands but heterodimerizes with ErbB1/EGF R, ErbB3, or ErbB4 to form higher affinity signaling complexes. The protease ADAM10 releases a 110 kDa soluble fragment of ErbB2 from the cell surface. ErbB2 plays roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation. The ErbB2/ErbB3 heterodimer is expressed in the majority of breast, skin, ovary and gastrointestinal tumors and transduces a highly mitogenic signal in response to neuregulin 1 (NRG1; heuregulin 1) or NRG2. ErbB3, ErbB2 and neuregulin are all required for formation of the sympathetic nervous system.
15 results for "ErbB2/Her2 Small Molecules and Peptides" in Products
15 results for "ErbB2/Her2 Small Molecules and Peptides" in Products
ErbB2/Her2: Small Molecules and Peptides
ErbB2, also called Neu and Her2, is a transmembrane glycoprotein in the ErbB family of tyrosine kinase receptors for EGF superfamily growth factors. ErbB2 is widely expressed in epithelial cells and over-expressed in a large number of breast carcinomas. ErbB2 has no identified ligands but heterodimerizes with ErbB1/EGF R, ErbB3, or ErbB4 to form higher affinity signaling complexes. The protease ADAM10 releases a 110 kDa soluble fragment of ErbB2 from the cell surface. ErbB2 plays roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation. The ErbB2/ErbB3 heterodimer is expressed in the majority of breast, skin, ovary and gastrointestinal tumors and transduces a highly mitogenic signal in response to neuregulin 1 (NRG1; heuregulin 1) or NRG2. ErbB3, ErbB2 and neuregulin are all required for formation of the sympathetic nervous system.
Potent and selective HER2 targeting Degrader (PROTAC®)
| Chemical Name: | 5-((7-(4-(3-((4-((4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)-6-methoxyquinazolin-7-yl)oxy)propyl)piperazin-1-yl)heptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
| Purity: | ≥98% (HPLC) |
Potent and selective ErbB2 inhibitor
| Chemical Name: | N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine |
| Purity: | ≥98% (HPLC) |
Potent irreversible pan ErbB inhibitor
| Alternate Names: | PF00299804 |
| Chemical Name: | (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide |
| Purity: | ≥98% (HPLC) |
EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor
| Alternate Names: | Tyrphostin AG 490 |
| Chemical Name: | (E)-2-Cyano-3-(3,4-dihydrophenyl)-N-(phenylmethyl)-2-propenamide |
| Purity: | ≥98% (HPLC) |
Potent HER2 receptor tyrosine kinase and EGFR kinase inhibitor
| Chemical Name: | (2E)-N-[4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide |
| Purity: | ≥98% (HPLC) |
Potent and selective dual ErbB2 (HER-2) and EGFR inhibitor
| Chemical Name: | N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine |
| Purity: | ≥98% (HPLC) |
Potent dual specificity EGFR/HER2 inhibitor; active in vivo
| Alternate Names: | BIBW2992 |
| Chemical Name: | (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide dimaleate |
| Purity: | ≥98% (HPLC) |
Highly potent EGFR and ErbB2 inhibitor; inhibts wild type and mutated receptors
| Chemical Name: | (4-Fluorophenyl)methyl N-[2-[(1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]-N-[3-[(1-oxo-2-propen-1-yl)amino]phenyl]carbamate |
| Purity: | ≥98% (HPLC) |
Potent EGFR PROTAC® Degrader; also degrades HER2
| Chemical Name: | (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6- yl)phenoxy)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
| Purity: | ≥98% (HPLC) |
Potent and selective ErbB2 inhibitor
| Alternate Names: | Mubritinib |
| Chemical Name: | 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-triazole |
| Purity: | ≥98% (HPLC) |
Potent dual EGFR/ErbB2 inhibitor; orally active
| Chemical Name: | N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[[[2-(methylsulfonyl)ethyl]amino]methyl]-4-thiazolyl]-4-quinazolinamine dihydrochloride |
| Purity: | ≥97% (HPLC) |
Negative control for PP 2 (Cat. No. 1407)
| Chemical Name: | 1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
| Purity: | ≥98% (HPLC) |
Potent EGFR and VEGFR inhibitor
| Chemical Name: | 6-[4-[(4-Ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| Purity: | ≥98% (HPLC) |
Potent EGFR PROTAC® Degrader
| Alternate Names: | Iressa-based PROTAC 3 |
| Chemical Name: | (2S,4R)-1-((S)-2-(3-(2-((5-((4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)oxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
| Purity: | ≥98% (HPLC) |
Potent ErbB receptor family inhibitor
| Chemical Name: | N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine |
| Purity: | ≥98% (HPLC) |
